Literature DB >> 23376320

Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis.

Ali Akbar1, Barham K Abu Dayyeh, Todd H Baron, Zhen Wang, Osama Altayar, Mohammad Hassan Murad.   

Abstract

BACKGROUND & AIMS: Placement of pancreatic duct (PD) stents prevents pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). There is evidence that rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) also prevents post-ERCP pancreatitis, but the 2 approaches alone have not been compared directly. We conducted a network meta-analysis to indirectly compare the efficacies of these procedures.
METHODS: PubMed and Embase were searched by 2 independent reviewers to identify full-length clinical studies, published in English, investigating use of PD stent placement and rectal NSAIDs to prevent post-ERCP pancreatitis. We identified 29 studies (22 of PD stents and 7 of NSAIDs). We used network meta-analysis to compare rates of post-ERCP pancreatitis among patients who received only rectal NSAIDs, only PD stents, or both.
RESULTS: Placement of PD stents and rectal administration of NSAIDs were each superior to placebo in preventing post-ERCP pancreatitis. The combination of rectal NSAIDs and stents was not superior to either approach alone. Pooled results showed that rectal NSAIDs alone were superior to PD stents alone in preventing post-ERCP pancreatitis (odds ratio, 0.48; 95% confidence interval, 0.26-0.87).
CONCLUSIONS: Based on a network meta-analysis, rectal NSAIDs alone are superior to PD stents alone in preventing post-ERCP pancreatitis, and should be considered first-line therapy for selected patients. However, these findings were limited by the small number of studies assessed (only 29 studies), potential publication bias, and the indirect nature of the comparison. High-quality, randomized, controlled trials are needed to compare these 2 interventions and confirm these findings.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376320     DOI: 10.1016/j.cgh.2012.12.043

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  32 in total

1.  The impact of prophylactic pancreatic stenting on post-ERCP pancreatitis: A nationwide, register-based study.

Authors:  Greger Olsson; Jeanne Lübbe; Urban Arnelo; Eduard Jonas; Björn Törnqvist; Lars Lundell; Lars Enochsson
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

2.  Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Yu Zhang; Xiaoling Ye; Xinyue Wan; Tao Deng
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

3.  Impact of pancreatic stent caliber on post-endoscopic retrograde cholangiopancreatogram pancreatitis rates in patients with confirmed sphincter of Oddi dysfunction.

Authors:  Jayapal Ramesh; Hwasoon Kim; Kartika Reddy; Shyam Varadarajulu; C Mel Wilcox
Journal:  J Gastroenterol Hepatol       Date:  2014       Impact factor: 4.029

Review 4.  Training in ERCP and EUS in the UK anno 2017.

Authors:  Noor Lh Bekkali; Gavin J Johnson
Journal:  Frontline Gastroenterol       Date:  2017-02-10

5.  Systematic review and meta-analysis on the prophylactic role of non-steroidal anti-inflammatory drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Muhammad S Sajid; Amir H Khawaja; Mazin Sayegh; Krishna K Singh; Zinu Philipose
Journal:  World J Gastrointest Endosc       Date:  2015-12-25

6.  Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?

Authors:  Zoltán Döbrönte; Zoltán Szepes; Ferenc Izbéki; Judit Gervain; László Lakatos; Gyula Pécsi; Miklós Ihász; Lilla Lakner; Erzsébet Toldy; László Czakó
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Endoscopic papillectomy, single-centre experience.

Authors:  Shamel Ismail; Udd Marianne; Järvinen Heikki; Halttunen Jorma; Kylänpää Leena
Journal:  Surg Endosc       Date:  2014-06-14       Impact factor: 4.584

Review 8.  Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: What does evidence suggest?

Authors:  Clotilde Fuentes-Orozco; Carlos Dávalos-Cobián; Jesús García-Correa; Gabriela Ambriz-González; Michel Dassaejv Macías-Amezcua; Jesús García-Rentería; Jorge Rendón-Félix; Mariana Chávez-Tostado; Lizbeth Araceli Cuesta-Márquez; Andrea Socorro Alvarez-Villaseñor; Ana Olivia Cortés-Flores; Alejandro González-Ojeda
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

9.  Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin.

Authors:  Xiaoyu Kang; Liyue Zheng; Wei Zeng; Shengye Yang; Hao Sun; Rongchun Zhang; Xiangping Wang; Biaoluo Wang; Qin Tao; Shaowei Yao; Jie Chen; Yanglin Pan; Xuegang Guo
Journal:  J Gastrointest Surg       Date:  2018-07-06       Impact factor: 3.452

Review 10.  Preventing Post-ERCP Pancreatitis: Update 2016.

Authors:  Martin L Freeman
Journal:  Curr Treat Options Gastroenterol       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.